(Q69367976)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2564111%20AND%20SRC:MED&resulttype=core&format=json

1 October 2019

title

Tumour-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2564111%20AND%20SRC:MED&resulttype=core&format=json

1 October 2019

1

R L Kradin

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2564111%20AND%20SRC:MED&resulttype=core&format=json

1 October 2019

author name string

J T Kurnick

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2564111%20AND%20SRC:MED&resulttype=core&format=json

1 October 2019

D S Lazarus

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2564111%20AND%20SRC:MED&resulttype=core&format=json

1 October 2019

F I Preffer

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2564111%20AND%20SRC:MED&resulttype=core&format=json

1 October 2019

S M Dubinett

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2564111%20AND%20SRC:MED&resulttype=core&format=json

1 October 2019

C E Pinto

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2564111%20AND%20SRC:MED&resulttype=core&format=json

1 October 2019

J Gifford

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2564111%20AND%20SRC:MED&resulttype=core&format=json

1 October 2019

E Davidson

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2564111%20AND%20SRC:MED&resulttype=core&format=json

1 October 2019

B Grove

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2564111%20AND%20SRC:MED&resulttype=core&format=json

1 October 2019

R J Callahan

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2564111%20AND%20SRC:MED&resulttype=core&format=json

1 October 2019

language of work or name

English

0 references

publication date

1 March 1989

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2564111%20AND%20SRC:MED&resulttype=core&format=json

1 October 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2564111%20AND%20SRC:MED&resulttype=core&format=json

1 October 2019

volume

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2564111%20AND%20SRC:MED&resulttype=core&format=json

1 October 2019

page(s)

577-580

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2564111%20AND%20SRC:MED&resulttype=core&format=json

1 October 2019

issue

8638

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2564111%20AND%20SRC:MED&resulttype=core&format=json

Selective in Vitro Growth of T Lymphocytes from Normal Human Bone Marrows

1 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2889%2991609-7

7 January 2021

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2889%2991609-7

7 January 2021

Interleukin-2 augments natural killer cell activity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2889%2991609-7

7 January 2021

Adoptive Immunotherapy of Established Pulmonary Metastases with LAK Cells and Recombinant Interleukin-2

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2889%2991609-7

7 January 2021

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2889%2991609-7

7 January 2021

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2889%2991609-7

7 January 2021

On lymphokines, cytokines, and breakthroughs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2889%2991609-7

7 January 2021

Functional characterization of T lymphocytes propagated from human lung carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2889%2991609-7

7 January 2021

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2889%2991609-7

7 January 2021

Increased vascular permeability in organs mediated by the systemic administration of lymphokine-activated killer cells and recombinant interleukin-2 in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2889%2991609-7

7 January 2021

Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2889%2991609-7

7 January 2021

Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2889%2991609-7

7 January 2021

Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2889%2991609-7

7 January 2021

10.1016/S0140-6736(89)91609-7

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2564111%20AND%20SRC:MED&resulttype=core&format=json

1 October 2019

1 reference